Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Some low-grade prostate cancers carry higher risks than biopsy suggests

2.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

3.

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot